A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

The study was prematurely discontinued on 14 September 2011 due to no significant
pharmacological effects (safety/PD/efficacy) through 25 mg/kg cohort, the T1/2 based on VEGF
binding was shorter than expected and the current and/or higher doses were not considered
feasible for further development. There were no safety concerns associated with the decision
to terminate the program/study.

Inclusion Criteria:

- Confirmed solid tumors unresponsive to current therapy or for which there is no
standard therapy.

- Stage 2 only: Histologically or cytologically documented EOC or PPC with < or equal
to 3 previous anti-cancer therapies, but at least 1 prior platinum containing
regimen.

- Adequate coagulation, liver, and renal function.

- Candidate for Dynamic Contrast-Enhanced Magnetic Resonance Imaging [DCE-MRI]
evaluation

- Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1

Exclusion Criteria:

- History of clinically significant toxicity to Vascular Endothelial Growth Factor
[VEGF] inhibition.

- Evidence of bleeding problems.

- Uncontrolled hypertension.

- Patients with primary brain cancer and/or non-small cell lung cancer of squamous cell
histology